- Home
- EVTC vs DNTH Comparison
EVTC vs DNTH Comparison
Compare EVTC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVTC | DNTH |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | EVTC | DNTH |
|---|---|---|
| Price | $29.71 | $52.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $35.80 | ★ $68.88 |
| AVG Volume (30 Days) | 330.7K | ★ 751.4K |
| Earning Date | 02-25-2026 | 03-10-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | ★ 76.90 | N/A |
| EPS | ★ 2.26 | N/A |
| Revenue | ★ $903,381,000.00 | $3,078,000.00 |
| Revenue This Year | $11.45 | N/A |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | $13.17 | ★ N/A |
| Revenue Growth | ★ 9.67 | N/A |
| 52 Week Low | $26.72 | $13.37 |
| 52 Week High | $38.56 | $54.00 |
Technical Indicators
Market Signals| Indicator | EVTC | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 72.76 |
| Support Level | $28.80 | $42.70 |
| Resistance Level | $30.28 | $54.00 |
| Average True Range (ATR) | 0.88 | 3.26 |
| MACD | -0.01 | 1.33 |
| Stochastic Oscillator | 60.13 | 90.91 |
Price Performance
Historical ComparisonAbout EVTC Evertec Inc.
Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions which derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. It derives maximum revenue from Latin America Payments and Solutions. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.